• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心房颤动患者缺血性卒中的病因及抗凝治疗

Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants.

作者信息

Purrucker Jan C, Hölscher Kyra, Kollmer Jennifer, Ringleb Peter A

机构信息

Department of Neurology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Department of Neuroradiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

出版信息

J Clin Med. 2020 Sep 11;9(9):2938. doi: 10.3390/jcm9092938.

DOI:10.3390/jcm9092938
PMID:32932971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7564370/
Abstract

BACKGROUND

Reducing the number of ischemic strokes in patients with atrial fibrillation despite oral anticoagulation remains an important, yet largely unsolved challenge. Therefore, we assessed the etiology of ischemic strokes despite anticoagulation with vitamin K antagonists (VKA) or non-VKA oral anticoagulants (NOACs).

METHODS

Patients with known atrial fibrillation (AF), treatment with VKA or NOAC, and acute ischemic stroke admitted between 2015 and 2018 (1st half) were identified from the hospital database. Brain imaging data were independently reviewed. An integrated etiologic classification according to the ASCOD system was made. Medication errors (admission INR <2.0 in the VKA- or NOAC-specific concentration <10 ng/mL) or dosage/dosing errors were also analyzed.

RESULTS

Of 3610 patients screened, = 341 were included (VKA, = 127; NOAC, = 214). An overall increasing rate of OAC-associated stroke per year was observed. In 95.3% of patients with adequate diagnostic work-up ( = 321/337), at least one additional potential, uncertain, or unlikely non-cardiac cause of stroke was identified. More patients in the VKA than in the NOAC group had a medication error (81/127, 63.8% vs. 102/205, 49.8%; = 0.013).

CONCLUSIONS

Stroke risk factors despite atrial fibrillation were highly prevalent. Although less common with NOACs than VKAs, medication errors are still frequent.

摘要

背景

尽管使用了口服抗凝药,但减少心房颤动患者的缺血性卒中数量仍然是一项重要但尚未得到充分解决的挑战。因此,我们评估了在使用维生素K拮抗剂(VKA)或非VKA口服抗凝剂(NOAC)进行抗凝治疗的情况下缺血性卒中的病因。

方法

从医院数据库中识别出2015年至2018年(上半年)期间已知患有心房颤动(AF)、接受VKA或NOAC治疗且发生急性缺血性卒中的患者。对脑成像数据进行独立审查。根据ASCOD系统进行综合病因分类。还分析了用药错误(VKA组入院时国际标准化比值<2.0或NOAC组特定浓度<10 ng/mL)或剂量/给药错误。

结果

在筛查的3610例患者中,纳入了341例(VKA组127例;NOAC组214例)。观察到每年OAC相关卒中的总体发生率呈上升趋势。在95.3%进行了充分诊断检查的患者(321/337)中,至少发现了一种其他潜在、不确定或不太可能的非心脏性卒中病因。VKA组用药错误的患者比NOAC组多(81/127,63.8%对102/205,49.8%;P = 0.013)。

结论

尽管存在心房颤动,但卒中危险因素仍然非常普遍。虽然与VKA相比,NOAC导致的用药错误较少见,但仍然很频繁。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79b0/7564370/9dd5c1d635d2/jcm-09-02938-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79b0/7564370/9cdb02cf9b83/jcm-09-02938-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79b0/7564370/8d0fc61965c9/jcm-09-02938-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79b0/7564370/9dd5c1d635d2/jcm-09-02938-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79b0/7564370/9cdb02cf9b83/jcm-09-02938-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79b0/7564370/8d0fc61965c9/jcm-09-02938-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79b0/7564370/9dd5c1d635d2/jcm-09-02938-g003.jpg

相似文献

1
Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants.心房颤动患者缺血性卒中的病因及抗凝治疗
J Clin Med. 2020 Sep 11;9(9):2938. doi: 10.3390/jcm9092938.
2
Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.在心房颤动患者中从维生素 K 拮抗剂转换为非维生素 K 拮抗剂口服抗凝剂:预测因素、模式和时间趋势。
BMC Cardiovasc Disord. 2021 Oct 13;21(1):493. doi: 10.1186/s12872-021-02295-w.
3
Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.心房颤动患者血尿后恢复口服抗凝治疗的发生率、后果以及缺血性卒中和大出血风险
J Thromb Thrombolysis. 2021 Jan;51(1):58-66. doi: 10.1007/s11239-020-02135-2.
4
Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.急性缺血性脑卒中患者的再通治疗:新型口服抗凝剂治疗对出血并发症和结局的影响。
Circulation. 2015 Sep 29;132(13):1261-9. doi: 10.1161/CIRCULATIONAHA.115.015484. Epub 2015 Jul 31.
5
Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation.非维生素K拮抗剂口服抗凝剂在现实世界中肥胖房颤患者中的临床疗效
Semin Thromb Hemost. 2020 Nov;46(8):970-976. doi: 10.1055/s-0040-1715792. Epub 2020 Oct 26.
6
Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.51,000 例有卒中风险的房颤患者一年内口服抗凝治疗的变化:一项源自实践的研究。
Thromb Haemost. 2019 Jun;119(6):882-893. doi: 10.1055/s-0039-1683428. Epub 2019 Mar 21.
7
Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.非维生素 K 拮抗剂口服抗凝剂和维生素 K 拮抗剂治疗的心房颤动患者的知识差异。
Kardiol Pol. 2018;76(7):1089-1096. doi: 10.5603/KP.a2018.0069. Epub 2018 Mar 12.
8
Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.未转换为新型口服抗凝药的维生素K拮抗剂治疗的房颤患者的选择、管理及结局。德累斯顿非维生素K拮抗剂口服抗凝药注册研究结果
Thromb Haemost. 2015 Nov;114(5):1076-84. doi: 10.1160/TH15-02-0116. Epub 2015 May 21.
9
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.2018 年欧洲心脏病学会关于非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中应用的实用指南。
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
10
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.在 1 年随访期间,接受稳定维生素 K 拮抗剂治疗或换用非维生素 K 拮抗剂口服抗凝剂的心房颤动患者的生活质量和患者满意度:AF 登记处的 PREFER 子研究。
Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21.

引用本文的文献

1
Before, during, and after: An Argument for Safety and Improved Outcome of Thrombolysis in Acute Ischemic Stroke with Direct Oral Anticoagulant Treatment.在急性缺血性脑卒中直接口服抗凝治疗中:溶栓治疗的安全性和预后改善的论证——从开始到结束。
Ann Neurol. 2024 Nov;96(5):871-886. doi: 10.1002/ana.27058. Epub 2024 Sep 11.
2
Characteristics and outcomes of atrial fibrillation detected before and after acute ischemic stroke.急性缺血性卒中前后检测到的心房颤动的特征与结局
J Neurol. 2024 Oct;271(10):6856-6865. doi: 10.1007/s00415-024-12671-z. Epub 2024 Aug 31.
3
Hemorrhagic Coagulation Disorders and Ischemic Stroke: How to Reconcile Both?

本文引用的文献

1
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.缺血性脑卒中与口服 Xa 因子抑制剂在房颤患者中的剂量调整。
J Neurol. 2020 Jul;267(7):2007-2012. doi: 10.1007/s00415-020-09795-3. Epub 2020 Mar 23.
2
Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation.心房颤动患者接受口服抗凝治疗后仍发生缺血性卒中
Ann Neurol. 2020 Feb 12;87(5):677-87. doi: 10.1002/ana.25700.
3
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
出血性凝血障碍与缺血性卒中:如何协调二者?
Neurol Int. 2023 Nov 30;15(4):1443-1458. doi: 10.3390/neurolint15040093.
4
Characteristics and Mechanism of Acute Ischemic Stroke in NAVF Patients With Prior Oral Anticoagulant Therapy.伴有抗凝治疗的非瓣膜性房颤患者急性缺血性脑卒中的特征及机制。
Neurologist. 2023 Nov 1;28(6):379-385. doi: 10.1097/NRL.0000000000000504.
5
Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy.口服抗凝药物单独或联合抗血小板治疗的心房颤动患者的卒中复发风险。
Eur Stroke J. 2023 Sep;8(3):722-730. doi: 10.1177/23969873231183211. Epub 2023 Jul 17.
6
The contribution of competing mechanisms in stroke despite anticoagulation in patients with atrial fibrillation.尽管在房颤患者中进行抗凝治疗,但竞争机制仍会导致卒中。
Eur Stroke J. 2023 Jun;8(2):541-548. doi: 10.1177/23969873231168367. Epub 2023 Apr 3.
7
Evaluation of Herb-Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes.丹参与利伐沙班在大鼠和人肝微粒体中的药草-药物相互作用评估。
Front Pharmacol. 2022 Jul 19;13:950525. doi: 10.3389/fphar.2022.950525. eCollection 2022.
8
Special Issue on "Disseminated Intravascular Coagulation: Current Understanding and Future Perspectives".“弥散性血管内凝血:当前认识与未来展望”特刊
J Clin Med. 2022 Jun 9;11(12):3315. doi: 10.3390/jcm11123315.
9
Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation.尽管在房颤患者中进行了口服抗凝治疗,但其缺血性脑卒中的病因、二级预防策略和结果。
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):588-598. doi: 10.1136/jnnp-2021-328391. Epub 2022 Apr 8.
10
Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units.直接口服抗凝剂治疗急性缺血性脑卒中合并非瓣膜性心房颤动患者的治疗标准:德国卒中单元的一项调查。
PLoS One. 2022 Feb 17;17(2):e0264122. doi: 10.1371/journal.pone.0264122. eCollection 2022.
急性缺血性脑卒中患者早期管理指南:2018 年急性缺血性脑卒中早期管理指南的更新:美国心脏协会/美国卒中协会发布的医疗保健专业人员指南。
Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30.
4
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南:通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
5
Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention.非维生素 K 拮抗剂口服抗凝剂预防卒中治疗的心房颤动患者的脑缺血事件的原因和危险因素。
Stroke. 2019 Aug;50(8):2168-2174. doi: 10.1161/STROKEAHA.119.025350. Epub 2019 Jun 25.
6
Cerebral Ischemia in Patients on Direct Oral Anticoagulants.直接口服抗凝剂治疗患者的脑缺血。
Stroke. 2019 Apr;50(4):873-879. doi: 10.1161/STROKEAHA.118.023877.
7
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.利伐沙班联合或不联合阿司匹林用于稳定型心血管疾病。
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
8
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.心房颤动卒中预防的变化格局:GLORIA-AF 注册研究 2 期结果。
J Am Coll Cardiol. 2017 Feb 21;69(7):777-785. doi: 10.1016/j.jacc.2016.11.061.
9
Pleiotropic Effects of Statins on the Cardiovascular System.他汀类药物对心血管系统的多效性作用
Circ Res. 2017 Jan 6;120(1):229-243. doi: 10.1161/CIRCRESAHA.116.308537.
10
Coagulation Testing in Acute Ischemic Stroke Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.服用非维生素K拮抗剂口服抗凝剂的急性缺血性中风患者的凝血检测
Stroke. 2017 Jan;48(1):152-158. doi: 10.1161/STROKEAHA.116.014963. Epub 2016 Nov 29.